drugset / Trial / NCT04477642
Abatacept for Patients With COVID-19 and Respiratory Distress
Phase 1/2
Withdrawn
Beth Israel Deaconess Medical Center
Boston Children's Hospital · collabBrigham and Women's Hospital · collabBristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm open label trial for hospitalized patients with COVID-19 (Coronavirus). The primary endpoint of the study is to assess the requirement for mechanical ventilation in patients who are admitted to the hospital with COVID-19 infection and a Pulse Oxygen Level \</= 93% on room air. The primary endpoint analysis will be performed using all enrolled patients.
Timeline
- Start
- 2020-08
- Primary completion
- 2020-10
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | 10 mg/kg | Intravenous |